Section 3 of 6
Product information and disease description
231 evidence topics · 121 sources
Product description
Phase of product development
Regulatory status: Submission planned; BLA planned on the basis of the phase 3 CAPTIVATE trial, with Part B top-line results expected by the end of 2028
Launch
No evidence found.
Single pivotal phase 3 trial announced, November 2024
Phase 3 CAPTIVATE trial initiated, February 2025
Interim responder analysis: early GO decision, March 2026
Trial resizing and removal of the 600 mg arm from Part B
FDA written feedback on antinuclear antibody screening and drug-induced lupus, March 2026
Orphan drug, fast track, or breakthrough therapy designation for CIDP
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Dianthus Therapeutics
Nonproprietary name: proposed and recommended international nonproprietary name
Brand name
No evidence found.
Structure: fully human IgG4-kappa antibody with an engineered Fc domain
Therapeutic class: classical complement pathway inhibitor targeting active C1s
Dosage forms and strengths
Intravenous loading dose followed by subcutaneous injection
Phase 3 subcutaneous presentation: prefilled syringe
Target commercial presentation: 300 mg/2 mL autoinjector
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
WHO INN class statement for claseprubart
WHO INN stem and target-class infix for monoclonal antibodies
WHO Anatomical Therapeutic Chemical group for complement inhibitors
AHFS class and ATC code assigned to claseprubart
No evidence found.
Indication
Indication under study: adults with CIDP
Eligible population: phase 3 CAPTIVATE inclusion criteria
Patient groups enrolled: treated, refractory, and treatment-naive
Pharmacology
Mechanism of action
Role of C1s in the classical complement pathway
Targeting of the small active fraction of circulating C1s
Binding selectivity for active C1s over proC1s
Upstream blockade of C3a, C3b, and membrane attack complex formation
Company description of the mechanism: latest statement
Pharmacodynamics
Classical pathway inhibition in healthy volunteers: phase 1
In vitro affinity and potency compared with riliprubart
| Assay | DNTH103 | Riliprubart |
|---|---|---|
| Binding affinity to human active C1s, KD (KinExa) | “9pM” | “75pM” |
| Binding affinity to human active C1s, KD (SPR) | “8pM” | “35pM” |
| C4 cleavage by human active C1s, IC90 (nM) | “0.47” | “3.69” |
| Wieslab classical pathway assay in human serum, IC90 (μg/mL) | “0.45” | “5.4” |
| CH50 assay of RBC lysis in human serum, IC90 (μg/mL) | “98” | “668” |
| Liposome lysis in human serum, IC90 (μg/mL) | “14.7” | “39.8” |
Restoration of nerve conduction velocity in an in vitro CIDP model
Pharmacokinetic, pharmacodynamic, and immunogenicity assessments in CAPTIVATE
Pharmacokinetics
Fc engineering for half-life extension
Phase 1 study design for pharmacokinetic assessment
Elimination half-life of approximately 60 days
Simulated steady-state exposure relative to the IC90
Observed steady-state concentration with 300 mg every 2 weeks: phase 2
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA written feedback on antinuclear antibody testing and the autoimmune risk description
Antinuclear antibody seroconversion: phase 2 randomized period
| Measure | Placebo (N=22) | Claseprubart 300mg/2mL Q2W (N=21) | Claseprubart 600mg/4mL Q2W (N=22) |
|---|---|---|---|
| Newly positive for anti-nuclear antibodies (ANA) | “0 (0%)” | “1 (5.9%)” | “8 (36.4%)” |
| Rashes | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Arthralgia | “1 (4.5%)” | “1 (4.8%)” | “0 (0%)” |
Antinuclear antibody testing removed from current trial protocols
Infection risk: rationale for sparing the lectin and alternative pathways
Infection risk: in vitro meningococcal killing assay
Infection and autoimmune events reported in clinical trials to date
Trial precautions: vaccination, complement deficiency, meningococcal history, and lupus
Extended half-life and duration of adverse effects
Special populations
Age ranges studied in claseprubart trials
Body weight ranges studied
Pregnancy, lactation, renal function, and hepatic function: phase 1 exclusions
Drug/Drug, drug/disease interactions
Effects of other drugs on Claseprubart
Intravenous immunoglobulin: phase 1 Part C pharmacokinetic study
Immunoglobulin switch and prior complement or anti-CD20 therapy: CAPTIVATE
Effects of Claseprubart on other drugs
No evidence found.
Dosing and administration
Dosage
CAPTIVATE regimen by study part
Part A and Part B dose: 300 mg subcutaneously every 2 weeks
Removal of the 600 mg Part B arm after the interim responder analysis
Switching from immunoglobulin and corticosteroids
Administration
Intravenous loading dose followed by subcutaneous injection
Prefilled syringe used in the phase 3 EMERGE trial
Target presentation: 300 mg/2 mL self-administered autoinjector
Formulation concentration and viscosity
Access and distribution
Contract manufacturing: WuXi Biologics
Cell line license and royalty on commercial supply from another manufacturer
Commercialization plans
Greater China license: Tenacia Biotechnology
Autoinjector device: SHL Medical Molly technology
Patent protection
Co-prescribed/Concomitant therapies
Prior and current CIDP treatment permitted at entry to the phase 3 trial
Corticosteroids, immunosuppressants, and immunoglobulin during the phase 3 trial
Rescue therapy and return to standard of care in the phase 3 trial
Required vaccination against encapsulated bacteria in the phase 3 trial
Treatment at study entry: interim analysis of the first 40 participants
| Prior treatment group | Claseprubart 300 mg every 2 weeks (N=40), n (%) |
|---|---|
| Standard of care treated | “27 (67.5)” |
| Immunoglobulin | “19 (47.5)” |
| Oral corticosteroids | “8 (20.0)” |
| Standard of care refractory | “9 (22.5)” |
| Treatment naive | “4 (10.0)” |
Effect of Claseprubart on quality measures
No evidence found.
Product comparison
Claseprubart: mechanism, route, dosing interval, and approval status
Immune globulin intravenous 10%: Gamunex-C
| Attribute | Prescribing information |
|---|---|
| Product and route | “GAMUNEX-C FlexBag, [immune globulin injection (human), 10%, caprylate/chromatography purified] for intravenous use.” |
| CIDP indication | “GAMUNEX-C FlexBag is indicated for the treatment of CIDP in adults to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.” |
| Mechanism of action in CIDP | “The precise mechanism of action in CIDP has not been fully elucidated.” |
| CIDP dosing and interval | “GAMUNEX-C FlexBag may be administered as a maintenance infusion of 1 g/kg (10 mL/kg) administered over 1 day or divided into two doses of 0.5 g/kg (5 mL/kg) given on two consecutive days, every 3 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2003” |
Immune globulin intravenous 10%: Privigen
| Attribute | Prescribing information |
|---|---|
| Product and route | “PRIVIGEN, Immune Globulin Intravenous (Human), 10% Liquid” |
| CIDP indication | “Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults (1.3)” |
| Limitation of use in CIDP | “PRIVIGEN maintenance therapy in CIDP has not been studied beyond 6 months.” |
| Mechanism of action | “The mechanism of action has not been fully elucidated” |
| CIDP dosing and interval | “Maintenance dose: 1 g/kg (10 mL/kg) administered in 1 to 2 infusions on consecutive days, every 3 weeks” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2007” |
Immune globulin intravenous 10%: Panzyga
| Attribute | Prescribing information |
|---|---|
| Product and route | “PANZYGA, (immune globulin intravenous, human - ifas) 10% Liquid Preparation” |
| CIDP indication | “Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults” |
| Mechanism of action in CIDP | “The mechanism of action of immunoglobulins in the treatment of CIDP in adults has not been fully elucidated.” |
| CIDP dosing and interval | “Maintenance dose: 1-2 g/kg (10-20 mL/kg) every 3 weeks divided in 2 doses given over 2 consecutive days” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2018” |
Immune globulin intravenous 10%: Gammagard Liquid
| Attribute | Prescribing information |
|---|---|
| Product | “GAMMAGARD LIQUID is an immune globulin infusion (human)” |
| CIDP indication | “Therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).” |
| Limitation of use in CIDP | “Safety and effectiveness of GAMMAGARD LIQUID has not been studied in immunoglobulin-naïve patients with CIDP.” |
| Route in CIDP | “CIDP: Intravenous (IV)” |
| Mechanism of action in CIDP | “The mechanism of action of immunoglobulins in the treatment of CIDP in adults has not been fully elucidated but may include immunomodulatory effects.” |
| CIDP dosing and interval | “Maintenance dose is 1 g/kg in divided doses over 1 to 4 consecutive days, every 3 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2005” |
Immune globulin subcutaneous 20%: Hizentra
| Attribute | Prescribing information |
|---|---|
| Product and route | “HIZENTRA is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Liquid” |
| CIDP indication | “HIZENTRA is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.” |
| Mechanism of action | “The mechanism of action has not been fully elucidated, but may include immunomodulatory effects.” |
| CIDP dosing | “Recommended subcutaneous dose is 0.2 g/kg (1 mL/kg) body weight per week.” |
| CIDP dosing interval | “CIDP: Administer weekly.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2010” |
Immune globulin 10% with recombinant human hyaluronidase: HyQvia
Neonatal Fc receptor blocker: Vyvgart Hytrulo
| Attribute | Prescribing information |
|---|---|
| Product | “VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase” |
| CIDP indication | “chronic inflammatory demyelinating polyneuropathy (CIDP)” |
| Mechanism of action | “Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Route | “VYVGART HYTRULO is for subcutaneous use only.” |
| Self-administration | “Prefilled syringe can be administered by patients and/or caregivers.” |
| CIDP dosing interval | “Administer as once weekly injections.” |
| CIDP dose, prefilled syringe | “Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over approximately 20 to 30 seconds.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |
Investigational C1s inhibitor riliprubart: phase 3 status
Investigational C2 inhibitor empasiprubart: phase 3 status
Investigational C2 inhibitor empasiprubart: placebo-controlled phase 3 trial registration (EMNERGIZE)
Investigational C2 inhibitor empasiprubart: head-to-head phase 3 trial registration against intravenous immunoglobulin (EMVIGORATE)
Place of product in therapy
Disease description
Definition and etiology
Disease definition: immune-mediated demyelinating disorder of the peripheral nerves and nerve roots
“Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disorder of the peripheral nerves and nerve roots causing limb weakness and sensory deficits” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CIDP is considered an immune-mediated disorder although the pathogenesis and aetiology of CIDP remain elusive” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Chronic inflammatory demyelinating polyradiculopathy (CIDP) is a symmetric, motor greater than sensory, proximal and distal demyelinating peripheral neuropathy with a slowly progressive or relapsing course.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CIDP is caused by primary immune‐mediated demyelination and secondary axonal damage in the peripheral nervous system, resulting in progressive muscle weakness and sensory impairment that led to significant disability” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Typical CIDP and CIDP variants in the EAN/PNS 2021 guideline
“Typical CIDP manifests as symmetrical sensorimotor neuropathy with proximal and distal limb involvement with absent or reduced tendon reflexes. Weakness must be more or less symmetric in all four limbs and the severity of proximal and distal weakness should be similar. Sensory disturbances are to be found in at least two limbs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CIDP variants, which were formerly referred to as atypical CIDP variants,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“are specific clinical syndromes that share the same signs that are supportive of demyelination and respond to the same therapies and are therefore considered to be on the same disease spectrum as sensorimotor CIDP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distribution of clinical phenotypes in national cohorts
“Typical CIDP was the most frequent subtype (52%), followed by distal (17%) and multifocal/focal CIDP (17%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 106 patients with typical CIDP (29%), 62 distal CIDP (17%), 28 multifocal or focal CIDP (7%), four sensory CIDP (1%), 27 sensory‐predominant CIDP (7%), 10 motor CIDP (3%), and eight motor‐predominant CIDP (2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: immune triggers and target antigens unidentified in most patients
“Though the exact triggers are unclear, diverse immune mechanisms encompassing cellular and humoral pathways are implicated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the trigger(s) for the autoimmune response and the target antigen(s) involved remain elusive in most patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A systematic screening of antibodies revealed a diverse antibody repertoire in CIDP patients, including those against NF-155 (4.6%), CNTN1 (6.2%), Caspr1/CNTN1 complex (1.5%), P2 (1.6%), and anti-ganglioside antibodies (18.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: older age, male sex, and diabetes mellitus
“The incidence rates increased with age for both sexes and were higher in males compared with females aged ≥55 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The finding that epidemiologic rates of CIDP were higher among males vs. females aged ≥55 years distinguishes CIDP from other autoimmune diseases, which are typically more prevalent in women across the lifespan” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common comorbidity was diabetes mellitus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only 1 of the 23 CIDP patients (4%) also had DM, whereas 14 of 115 age- and sex-matched controls (12%) had DM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diabetes mellitus (DM) is unlikely to be a major risk covariate for CIDP, but we cannot exclude a small effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Chronic inflammatory demyelinating polyneuropathy
United States: claims-based incidence, 2023
“After adjusting for age and sex and extrapolating to the US population, the estimated incidence rate was 2.8 (95% CI 2.7–2.9) per 100,000 persons or approximately 9,238 patients diagnosed with CIDP in 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“corresponding to a raw incidence rate of 2.2 (95% CI 2.0–2.3) per 100,000 persons in 2023” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were identified as having CIDP if they had 2 or more claims containing ICD-10 codes for CIDP (G61.81) separated by 30 or more days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this analysis, the incidence estimate decreased and prevalence estimate increased compared to our 2019 analysis, for which we calculated an adjusted incidence rate of 3.6 per 100,000 persons per year” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: Olmsted County, Minnesota, population-based incidence, 1982 to 2001
“To determine the incidence (1982–2001) and prevalence (on January 1, 2000) of CIDP in Olmsted County, Minnesota, and whether DM is more frequent in CIDP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of CIDP was 1.6/100,000/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global pooled incidence: systematic review and meta-analysis
“The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21–0.53; I2 = 95.7%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Crude incidence rates varied between 0.15 and 0.70 cases per 100,000 person-years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled crude incidence rate for studies using the AAN criteria is 0.36 per 100,000 person-years (95% CI 0.30–0.44, I2 = 0.0%; prediction interval 0.30–0.44).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In general, the reported crude incidence rates were higher in males than females (gender rate ratios varied between 1.5 and 4.0; Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
South Korea: nationwide claims-based incidence, 2016 to 2020
Iceland: population-based incidence, 1991 to 2011
Prevalence of Chronic inflammatory demyelinating polyneuropathy
United States: claims-based prevalence and estimated number of persons, 2023
“The adjusted rate was 23.3 (95% CI 23.1–23.5) per 100,000 persons, which corresponds to an estimated 77,058 individuals living with CIDP in the USA in 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“corresponding to a raw prevalence rate of 16.8 (95% CI 16.5–17.2) per 100,000 persons” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we calculated an adjusted incidence rate of 3.6 per 100,000 persons per year and an adjusted prevalence rate of 18.0 per 100,000 persons to estimate that 58,405 individuals were living with CIDP in the USA in 2019” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the medical claim codes used in this study may reflect suspected CIDP and may not represent a confirmed clinical diagnosis of CIDP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: Olmsted County, Minnesota, population-based prevalence, 2000
United States: accuracy of CIDP diagnosis codes in claims data
“The PPV of the algorithm requiring at least one CIDP diagnosis code before IVIG use was 66.2% (95% confidence interval [CI], 58.0-74.3). The PPV improved to 71.2% (62.7-79.6) when requiring at least two CIDP codes before IVIG use. The PPV for patients with at least one CIDP code who met the European Academy of Neurology/Peripheral Nerve Society 2021 diagnostic criteria was 30.0% (22.1-37.9).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global pooled prevalence: systematic review and meta-analysis
“the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58–4.39; I2 = 99.1%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The crude prevalence rate varied between 0.67 and 7.7 cases per 100,000 persons (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Japan: nationwide survey prevalence
“The primary survey showed that the estimated number of patients with CIDP was 4,180, with a prevalence of 3.3 per 100,000 persons.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The male-to-female ratio was 1.5:1, and the median age at onset was 52 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
South Korea: nationwide claims-based prevalence, 2020
United States: patients identified among 6.5 million commercial health plan members, 2011
“CIDP patients from 9 U.S. commercial health plans with claims in 2011 were identified from the Accordant Health Services claims database.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From 6.5 million covered lives, 73 (56% men; mean age 47) met study entry criteria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Disease course: progressive, monophasic, or relapsing-remitting
“The clinical course was progressive in 6, monophasic in 7, and relapsing–remitting in 10.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Remission and long-term treatment dependence
“The pooled rate of remission was 40.8% (95% CI, 30.6% to 51.8%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 51 participating patients had a median disease duration of 16 (interquartile range, 14-21) years. Twenty-seven patients (53%) had discontinued therapy and 46 walked independently.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: pooled case fatality rate across long-term outcome studies
Mortality compared with the general population: Iceland
“The standardized mortality ratio for the 21-year study period was 0.9 (95% CI 0.3-2.2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Many had no or only limited disease progression over the years and mortality is not increased compared with the general population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
In-hospital mortality and its predictors: South Korea
“Furthermore, 129 (13.50%) patients were treated in an ICU, and 80 (8.40%) died while receiving treatment at a medical institution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Age and the Elixhauser Comorbidity Index were associated with the in-hospital mortality of patients with CIDP. Infection and cardiovascular disease (CVD) were also significantly associated with the in-hospital mortality of those patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality in the United States
No evidence found.
Pathophysiology
Cellular and humoral immune mechanisms leading to macrophage-mediated demyelination
“The pathogenesis of CIDP involves a complex interplay of multiple aberrant immune responses, creating a pro-inflammatory environment, subsequently inflicting damage on the myelin sheath.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Histopathological changes in CIDP include breakdown of the blood–nerve barrier (BNB), segmental demyelination near the nodes of Ranvier, interstitial edema, and endoneurial inflammatory cell infiltration, including lymphocytes and macrophages and varying degrees of admixed axonal damage” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The response to plasma exchange therapy indicates the important role of circulating factors in CIDP pathogenesis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement activation pathways: the classical pathway is initiated through the C1 complex
“Complement activation occurs through three different pathways: classical (C1q), lectin (mannose-binding lectins or ficolin), and alternative (C3 autoactivation or properdin), which converge at C3, the most abundant complement protein found in the blood” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subsequently, the effector proteins C3a, C3b, and C5a and the membrane attack complex (MAC, C5b-9) are generated for target cell lysis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The complement system appears to play a role in promoting macrophage-mediated demyelination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement deposition in sural nerve biopsies
“Overall, 94% (n = 52) revealed abnormal and prominent deposition of terminal complement complex C5b-9 on endoneurial capillaries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, there was no complement deposition in NDC nor DC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C4d was deposited on the myelin sheaths in all patients with CIDP, with significantly higher density and intensity than in controls. C3c was detected in three of the nine patients with CIDP, while C5b-9 was not detected.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The classical and/or lectin pathways are predominantly involved in CIDP pathogenesis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In an early study, sural nerve biopsy specimens from seven patients with chronic relapsing demyelinating polyneuropathy showed deposition of IgM in intraneural blood vessels in all patients and deposition of C3 in six of the seven patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systemic complement activation in serum and cerebrospinal fluid
“Serum levels of activated complement proteins—C3a, C4a, Ba, Bb, C5a, and the soluble terminal complement complex sC5b-9 (sTCC)—were significantly elevated in CIDP patients compared to healthy donors (HD)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, concentrations of complement proteins indicative for more proximal activation of the classical and lectin (C1q, C4a, C4) pathway as well as of the alternative pathway (Ba, Bb) were also strikingly increased in CIDP compared to both CMT and HD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among CIDP patients, those with active, unstable disease exhibited significantly higher levels of terminal complement components (C5a and sTCC) compared to patients with stable disease or in remission” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A study compared serum and CSF levels of C5a and terminal complement complex (TCC) in 21 newly diagnosed, treatment-naïve CIDP patients, with that of 29 control patients with noninflammatory neurological diseases. CIDP patients had significantly higher mean serum and CSF levels of C5a and TCC than control patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Classical pathway inhibition at C1s in a human cell-based model of demyelinating neuropathy
“Patient autoantibody binding was sufficient to activate the classical complement pathway resulting in detection of C3b and C5b-9 deposits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TNT005 rescued the serum-induced complement deposition and functional deficits while treatment with an isotype control antibody had no rescue effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A human CIDP model was created by treatment of Schwann cell and motoneuron cultures with CIDP patient-derived serum, which triggered classical complement pathway activation and, subsequently, the deposition of C3b and C5b-9. Furthermore, treatment with a test monoclonal antibody inhibitor of C1s, TNT005, resulted in abrogation of complement deposition and rescued the electrophysiological deficits” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement-independent mechanisms in IgG4 paranodal antibody disease
“It is noteworthy that almost all the antibodies to these paranodal antigens were IgG4, an IgG subclass that is non-complement fixing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonetheless, some variants of these neuropathies harbor IgG1-3 subclass of antibodies with ability to fix complement and could potentially be candidates to complement inhibition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The IgG4 antibodies exert pathogenic effects on their targeted antigens by blocking enzymatic activity or disrupting protein–protein interactions affecting signal transduction pathways, but not by activating complement, binding to inhibitory FcγRIIb receptor or engaging in cross-linking of the targeted antigen with immune complex formation as the IgG1-IgG3 antibody subclasses do.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
EAN/PNS 2021 guideline: two levels of diagnostic certainty and supportive criteria
“Some notable changes from the previous guideline include the removal of distinctions between “definite” and “probable” conduction blocks, consolidating them into a singular category of conduction blocks. Furthermore, tibial nerve conduction blocks are no longer included and the threshold for temporal dispersion in the tibial nerve has been adjusted to necessitate at least a 100% increase in CMAP duration. Sensory criteria have transitioned from being merely supportive to being integral to the electrodiagnostic criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic accuracy of the EAN/PNS 2021 criteria compared with the EFNS/PNS 2010 criteria
“We included 339 patients and 339 matched controls. Sensitivity of the 2010 EFNS/PNS guideline was 92% when including possible CIDP and 91% for probable/definite CIDP, with specificities of 67% and 78%, respectively. For the 2021 EAN/PNS guideline, sensitivity was 94% when including possible CIDP and 83% for CIDP, with specificities of 66% and 86%, respectively. Differences were due to sensory criteria and changes in conduction block criteria. Unilateral NCS would miss 77 possible CIDP diagnoses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Misdiagnosis in the United States: referred patients who did not meet diagnostic criteria
“Forty-seven percent of patients referred with a diagnosis of CIDP failed to meet minimal CIDP diagnostic requirements.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CIDP misdiagnosis is common. Over-reliance on subjective patient-reported perception of treatment benefit, liberal electrophysiologic interpretation of demyelination, and placing an overstated importance on mild or moderate cytoalbuminologic dissociation are common diagnostic errors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-nine of 86 patients were found not to have CIDP. Initial electrodiagnostic data quality was generally acceptable, but initial electrodiagnostic conclusions were confirmed in only 45% of misdiagnosed studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Overdiagnosis and underdiagnosis at a European referral center
“A referral diagnosis of CIDP was revised in 32% of patients (31/96; overdiagnosis). Of 81 patients diagnosed with CIDP, 16 (20%) were referred with another diagnosis (underdiagnosis).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diagnostic pitfalls include lack of attention to proximal muscle weakness as a diagnostic hallmark of CIDP, insufficient recognition of clinical atypical phenotypes, overreliance on CSF protein levels, misinterpretation of nerve conduction studies and poor adherence to electrodiagnostic criteria, and failure to exclude other causes of polyneuropathy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Initial misdiagnosis and diagnostic delay in a multinational survey
Clinical presentation - signs and symptoms
Motor symptoms: symmetric proximal and distal limb weakness
“At initial admission, the most common symptoms were weakness (100% of typical CIDP, 91% of CIDP variants), sensory disturbances (97% of typical CIDP, 93% of CIDP variants), and/or ataxia (both 56%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The following two commonly reported symptoms had larger ranges between regions, with distal muscle weakness ranging from 42.3% in the US to 75.7% in Japan, and peripheral tingling ranging from 21.7% in China to 64.4% in Europe” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sensory symptoms: numbness, tingling, and sensory ataxia
Neurological signs: reduced or absent tendon reflexes
Movement symptoms: tremor and myoclonus
“Of the 124 included CIDP patients, 86 patients (69%, 95% CI 61 to 77%) currently had clinically tremulous movements (CTM), mainly consisting of tremor but also of myoclonus or both. Lifetime prevalence was 76% (95% CI 68 to 83%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CTM were associated with CIDP-related and tremor-related disability and upper arm sensory impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fatigue
“For all patients, the mean (SD) FACIT fatigue score was 35.0 (11.1). The majority of patients (52.7%) had scores between 36 and 51. Around one in ten (10.6%) scored between 0 and 19, indicative of severe fatigue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Autonomic symptoms: sudomotor, cardiovagal, gastrointestinal, and genitourinary dysfunction
“Autonomic symptoms were uncommon, mainly gastrointestinal (9/47; 19%) and genitourinary (8/47; 17%). Autonomic deficits (CASS ≥1) were frequent (22/47; 47%) but very mild (CASS, 0.8 ± 0.9; CASS ≤3, all cases). Deficits were predominantly sudomotor (16/47; 34%) and cardiovagal (10/47; 21%) with relative adrenergic sparing (4/47; 9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-four (89%) patients had features of autonomic dysfunction. Thirty-three (86%) patients had cardiovagal dysfunction, 21 (55%) had adrenergic dysfunction, and 24 (63%) had sudomotor dysfunction. Autonomic dysfunction was mild to moderate in the majority (86%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cranial nerve involvement in the multifocal variant
Long-term morbidity
Long-term disability and loss of ambulation
“The pooled fraction of nonambulatory patients was 8.2% (95% CI, 5.7% to 11.6%) and, overall, 47.1% (95% CI, 39.5% to 54.9%) of CIDP patients had a good outcome without disability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Use of mobility aids
“Overall, 47.3% of patients with CIDP (ranging from 41.7% in Japan and 50.0% in China) were recorded to use mobility aids at the time of data collection. Across all regions, a cane/walking stick was used by 35.3% of patients, followed by the wheeled walker (8.0%), walking frame, and/or manual wheelchair (both 4.9%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment delay and accumulation of irreversible disability
“Prolongation of time until start of therapy was associated with an increased burden of long-term disability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment initiation within 1 year of onset was significantly associated with lesser post‐treatment disability and greater amplitude of treatment response, in each cohort separately, and in the combined cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Early treatment initiation is a key modifiable determinant of favorable long‐term disability in CIDP. These findings underscore the importance of timely diagnosis and prompt treatment to prevent irreversible axonal damage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who started their initial treatment later experienced a worsening disease course, as reflected by a significant deterioration in their Inflammatory Neuropathy Cause and Treatment (INCAT) leg disability score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Refractory disease despite standard-of-care therapy
“Overall, 110 (56%) patients responded to their first therapy and were thus assigned to the status SOC-responder” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“76 (39%) patients did not respond to their first therapy and were assigned to the status SOC-refractory” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SOC-refractory patients had worse clinical outcomes than SOC-responders. Associated factors for SOC-refractory status included the presence of fatigue as a symptom and alcohol dependence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cancer risk compared with the general population
“The observed number of cancer diagnoses corresponded to an incidence rate of 5.63%, with a standardized incidence ratio (SIR) of 2.83 (95% confidence interval [CI]: 1.89–4.39) compared to the expected cancer incidence rate of 2.00%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Chronic inflammatory demyelinating polyneuropathy
Humanistic burden and health-related quality of life
Pain, fatigue, depression, and EQ-5D and SF-36 scores: systematic review of 7 humanistic burden studies
“Humanistic burden studies reported on the patient impact of CIDP on health-related quality of life (HRQoL), functioning, psychosocial welfare, productivity, pain, and fatigue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“2009 assessed pain and fatigue, using the Numeric Pain Rating Scale (NPRS) and Fatigue Severity Scale (FSS) scores (n = 76), reporting that 17 and 74% of patients with CIDP reported severe pain and severe fatigue, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two publications reported that 9 and 12.1% of patients had depression, based on hospital anxiety and depression scale (HADS) and the Beck Depression Inventory version II (BDI-II) scores in The Netherlands and Germany, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“EuroQol-5D (EQ-5D) scores among patients with CIDP were 0.62 and 0.68 for the UK and Germany, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A study of Dutch patients with CIDP (n = 76) also identified that patients scored below normative 36-Item Short Form Survey Instrument (SF-36) scores (50) for all the domains of the physical component and two of the domains of the mental component (vitality and social functioning)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-5L utility, fatigue, and disability in 1056 patients from eight countries, including the United States
“Data were drawn from the Adelphi CIDP Disease Specific Programme, a cross‐sectional survey with retrospective data collection, conducted in China, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States between September 2022 and April 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 164 physicians provided data for 1056 patients, with 428 (40.5%) providing self‐reported data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, mean (SD) patient‐reported scores were 62.1 (20.4) for I‐RODS, 35.0 (11.1) for FACIT fatigue, and 0.662 (0.253) for EQ‐5D‐5L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on mean EQ‐5D‐3L norms in the UK (0.856) and mean EQ‐5D‐5L norms in Germany (0.88), patients experience lower HRQoL in comparison to the general population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-3L utility and work productivity in 146 patients stable on immunoglobulin in the United States, the United Kingdom, and Germany
“Overall, 146 patients, 52 caregivers, and 81 physicians completed the survey; mean (standard deviation) patient age was 58.1 (12.8) years; time since CIDP diagnosis was 8.8 (9.3) years; 98.6% had received IVIG, and 30.8% had received SCIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) EQ-5D-3L utility index and EQ-5D VAS scores in the patient cohort were 0.68 (0.23) and 62.3 (19.4), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported that CIDP prevented them (quite a bit or very much) from performing activities (50.7%), affected their social activities with family and friends (39.7%), and imposed financial burden (37.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who were currently employed, mean (SD) WPAI total productivity impairment pertaining to CIDP was 37.9% (26.6)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-state utility values by adjusted INCAT impairment level from EQ-5D data collected in ADHERE
“0.851 for very limited impairment” (opens the source at this quote in a new tab)
“0.630 for mild impairment” (opens the source at this quote in a new tab)
“0.426 for moderate impairment” (opens the source at this quote in a new tab)
“0.084 for severe impairment” (opens the source at this quote in a new tab)
“-0.216 for very severe impairment.” (opens the source at this quote in a new tab)
SF-36 improvement with immune globulin IV 10% versus placebo in 117 trial participants
“One hundred seventeen patients in a randomized, double-blind, response-conditional crossover trial received immune globulin IV, 10% caprylate/chromatography purified (IGIV-C [Gamunex(R)]), or placebo every 3 weeks for up to 24 weeks in the first period (FP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the FP, greater improvements in both SF-36 physical and mental component scores were observed with IGIV-C vs placebo, with a significant improvement in the physical component score (difference 4.4 points; 95% confidence interval [CI] 0.7-8.0).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the EP, mean SF-36 improvements were generally improved or maintained in participants who continued IGIV-C therapy; however, worsening was observed in participants re-randomized to placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life measures in chronic inflammatory neuropathies: systematic review
“There is some evidence suggesting that baseline pre-treatment HRQoL reports are lower in patients with chronic inflammatory neuropathy than in age and gender-matched controls.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Following treatment interventions, improvements in self-reported measures were consistently documented in the physical domain of HRQoL, which in turn correlated with improvements in traditional strength and functional scales.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The impact of available treatments on the quality of life of patients with inflammatory neuropathies remains largely under-investigated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Changes in work and home life in a global survey of 595 respondents with self-reported CIDP
“Data from an online survey of 595 individuals with self-reported CIDP, recruited by the Guillain–Barré syndrome (GBS)/CIDP Foundation, were used to assess disease and treatment burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In "likely" CIDP patients 44% stopped working because of their symptoms and 24% moved to a new home.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IVIg was associated with venous access issues and work/school absenteeism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CIDP diagnostic confirmation was not performed in any of the survey respondents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Two-year all-cause costs and resource use versus matched controls in 790 newly diagnosed US adults
“This retrospective case-control analysis was conducted using data from the IQVIA Real-World Data Adjudicated Claims.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The final sample comprised a total of 790 cases matched to 790 controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cases had 7.5x higher mean total costs ($116,330 vs. $15,586, p<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Important cost drivers were costs for outpatient ancillary, radiology and HCPCS drugs (mean $76,366 vs. $4,292) and costs for inpatient care (mean $16,357 vs. $2,862) (both p<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among cases, CIDP therapy (inclusive of both outpatient pharmacy and medical claims) accounted for 51.2% of mean total costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From treatment initiation to the end of the 24-month follow-up, corticosteroid patients had mean (SD) CIDP therapy costs of about $7,900 ($35,000) while IVIg patients had mean CIDP therapy costs of $165,000 ($170,000).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-year all-cause costs by immunoglobulin use pattern in 3409 US adults
| Measure, year 1 after index | Value |
|---|---|
| All-cause outpatient visits, all patients | “31.74” |
| All-cause inpatient days, patients with at least 1 visit | “2.40” |
| Mean all-cause total cost, all patients | “$105,554” |
| Mean annual all-cause total cost, chronic immunoglobulin users | “$247,456” |
Two-year CIDP-specific costs by treatment cohort in US commercial claims
“This retrospective cohort study evaluated the treatment patterns and CIDP-related healthcare costs over a 2-year follow-up period for patients with newly diagnosed CIDP who had commercial insurance, using claims data from the IMS LifeLink PharMetrics Plus Claims database between 2009 through 2014.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean total CIDP-specific 2-year follow-up costs were highest for the cohort that received IVIG alone ($119,928) or with an additional therapy ($133,334) and lowest for patients who received active surveillance ($3723) or steroids alone ($3101).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When costs by site of care were investigated, the majority of IVIG infusion costs were found to be in the home rather than in the clinic or hospital setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost of illness and cost drivers in the United Kingdom, France, Germany, and the United States: systematic review
“CIDP cost of illness varied across geographies, from £22,086 (2007 costs) annually per patient in the UK, through €47,823 (2017 costs) and €45,000 (2013 costs) annually per patient in France and Germany, respectively, to $116,330 (costs converted to USD 2016 values) over 2 years in the USA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, in the US, drug-related costs represented 57% of total costs, followed by inpatient and outpatient hospital services (35%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the US, the majority of IVIG infusions occurred at home (72%), followed by physician offices (16%) and outpatient hospitals (11%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the UK, loss of productivity was estimated to cost £5815 per patient per year, and projected to cost the UK economy a total of £9.7 M per year, accounting for 26% of the total cost of illness” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quarterly societal costs and the share attributable to immunoglobulin in 108 patients in Germany
“In total, 108 patients were recruited from 3 specialized neuroimmunological clinics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Total quarterly costs were €11,333. Direct costs contributed to 83% of total costs (€9,423), whereas indirect costs accounted for 17% (€1,910) of total costs. The cost of intravenous immunoglobulin (IVIg) was the main determinant of total costs (67%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Reduced health-related quality of life and depressive symptoms were identified as independent predictors of higher total costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalizations, mobility aids, and productivity losses by disability level in 542 patients in five European countries
“Neurologists provided data on treatment, informal care, hospitalizations, mobility aids, and home modifications for 542 patients, while lost productivity was reported by a subset of patients ( n = 199).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hospitalizations in the 12 months prior to the survey were more frequent with greater disability (mild 7.0%, moderate 14.5%, severe 21.6%; p < 0.001), as were emergency admissions (1.0, 9.9, 13.7% respectively; p < 0.001) and ICU stays (0.0, 0.7, 3.9% respectively; p = 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of mobility aids (19.1, 56.1, 89.7% respectively) and home modifications (12.8, 45.8, 74.2% respectively) also rose significantly with severity ( p < 0.001 for both).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, work productivity losses among employed patients and activity impairment rose as disability increased (average percentage of productivity loss: mild 21.8%, moderate 44.0%, severe: 67.3%, p < 0.001; average daily activity impairment: mild 28.6%, moderate: 44.6%, severe: 68.1%, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As shown in Figure 4A , the proportion of patients employed at the time of the survey decreased with increasing disability severity (mild: 71.4%; moderate: 69.8%; severe: 39.1%; p = 0.049).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual immunoglobulin costs per person and savings from cessation trials in a UK center
“IVIg is a relatively scarce and expensive resource at a cost of £71/g, with immunomodulatory use representing £300 million per year of National Health Service (NHS) UK spending, and similar expenditure in other high income countries” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median cost of IVIg was £97 705 per person/year, at a median frequency of 2.4 days/month in the day care unit (£9213 per person/year), giving a total median cost of £106 918 per person/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cost saving associated with successful IVIg cessation in eight individuals was £855 344 per year, including IVIg spend and daycare unit costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual cost of immunoglobulin maintenance treatment by route of administration in Spain
“A cost-analysis model based on a decision tree was developed to evaluate the annual cost per patient treated with each immunoglobulin from a societal perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annual cost for a patient with CIDP receiving maintenance treatment was €109,212.67 with IVIG, €98,161.97 with c-SCIG, and €98,191.37 with f-SCIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main driver of the difference between SCIG and IVIG cost was treatment administration (−€10,705.78).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual health plan paid cost per patient and share attributable to immunoglobulin in US commercial health plans, 2011
“The most prescribed therapies were intravenous immunoglobulin (IVIg) (26% of patients), gabapentin (26%), and prednisone (16%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The annual health plan paid cost was $56,953. Pharmacy cost was the major cost driver (57% of the total), and IVIg totaled 90% of the pharmacy costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Chronic inflammatory demyelinating polyneuropathy on families
Informal caregiving hours and effect on caregiver employment in 542 patients in five European countries
“In the overall sample, 26.7% of patients required a caregiver, with a mean of 9.1 h of care per week (SD: 24.1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The partner or spouse was the primary caregiver in 84.3% of cases, and caregiving affected the caregiver’s work and daily activities in 41.4 and 78.9% of cases, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As shown in Figure 1A , the proportion of patients requiring informal (unpaid) care increased significantly with disability (mild: 7.2%; moderate: 31.2%; severe: 62.9%; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A work-related impact was reported in 20.0, 35.3, and 52.0% of caregivers for patients with mild, moderate, and severe disability, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most reported work-related impacts were reduced working hours (mild: 0.0%; moderate: 26.5%; severe: 20.0%) and cessation of work (mild: 13.3%; moderate: 0.0%; severe: 16%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver use and hours of care in a US real-world survey
Caregiver health-related quality of life, productivity, and financial burden in 52 caregivers
“Most patients and caregivers were from the USA (87.0% and 65.4%, respectively; Table 1 ), whereas the distribution of physicians was more even across the USA, the UK, and Germany” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among caregivers, mean (SD) EQ-5D-3L utility index and EQ-5D VAS scores were 0.79 (0.28) and 76.8 (15.6), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More than a quarter (28.8%) of the caregivers reported that CIDP affected (quite a bit or very much) their social activities with family and/or friends, while 36.5% reported that CIDP imposed financial burden on themselves and their family.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among caregivers who were employed, mean (SD) WPAI total productivity impairment pertaining to CIDP was 30.8% (21.0)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Carer utility decrement applied in the NICE appraisal of efgartigimod
Caregiver disutility removed from the CDA-AMC reanalysis of efgartigimod
Economic impact of diagnostic testing
Misdiagnosis in 59 consecutive patients referred to a US center with a diagnosis of CIDP
“A retrospective study of 59 consecutive patients referred with a diagnosis of CIDP was performed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-seven percent of patients referred with a diagnosis of CIDP failed to meet minimal CIDP diagnostic requirements.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients frequently reported improvements after being treated with immunotherapy, even if the CIDP diagnosis was incorrect.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over-reliance on subjective patient-reported perception of treatment benefit, liberal electrophysiologic interpretation of demyelination, and placing an overstated importance on mild or moderate cytoalbuminologic dissociation are common diagnostic errors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Electrodiagnostic interpretation errors in 86 referred patients
“Thirty-nine of 86 patients were found not to have CIDP. Initial electrodiagnostic data quality was generally acceptable, but initial electrodiagnostic conclusions were confirmed in only 45% of misdiagnosed studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Overdiagnosis and immunoglobulin exposure before referral at a Dutch tertiary center
“A referral diagnosis of CIDP was revised in 32% of patients (31/96; overdiagnosis).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the overdiagnosed patients, 20% of muscle weakness was asymmetric, 48% lacked proximal muscle weakness, 29% only had distal muscle weakness, 65% did not fulfil the electrodiagnostic criteria for CIDP, 74% had an elevated cerebrospinal fluid (CSF) protein level, and 97% had another type of neuropathy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment Before referral, 52% of overdiagnosed patients ( n = 16) were treated for CIDP with intravenous immunoglobulins (IVIg; n = 12), corticosteroids ( n = 1), or IVIg and corticosteroids ( n = 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Initial misdiagnosis and diagnostic delay in 1056 patients from eight countries
Electrodiagnostic testing before immunoglobulin initiation in 3975 US claims patients
“Of 32,090 patients with CIDP identified, 3975 (mean age 57 years) subsequently initiated IVIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CIDP-related laboratory/diagnostic procedures were performed in approximately 20– > 40% of patients in the 3 months prior to IVIG initiation (63.7% underwent electrodiagnostic/nerve conduction testing in the 6 months prior to IVIG initiation).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, some patients received IVIG therapy in the absence of electrodiagnostic or nerve conduction tests.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Electrophysiological findings as a US payer requirement for immunoglobulin coverage
“Several US payers mandate positive electrophysiological findings on at least three of four tests (per guidelines from the American Academy of Neurology [AAN]) as part of medical necessity for CIDP treatment, particularly intravenous immunoglobulin (IVIg)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment cost in Charcot-Marie-Tooth disease misdiagnosed as CIDP compared with the cost of genetic testing
“Among 1104 CIDP cases, we identified 35 CMT patients misdiagnosed as CIDP (3.2%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment cost in these 35 misdiagnosed patients was estimated at 4.6 million euros (M€), whereas the cost of CMT genetic analysis in 1104 patients was estimated at 2.7 M€.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, the cost of treating these 35 misdiagnosed patients was significantly higher than the cost of performing CMT genetic analysis in 1104 patients (4.6 M€ vs. 2.7 M€), suggesting that CMT genetic investigations should be more widely used before diagnosing CIDP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs of POEMS syndrome misdiagnosed as CIDP and cost-effectiveness of VEGF testing
“Delay in diagnosis is common with 55% of patients initially incorrectly diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment associated with an incorrect CIDP diagnosis led to total wasted healthcare expenditures of between £808 550 and £1 111 756 across our cohort, with an average cost-per-POEMS-patient misdiagnosed of £14 701 to £20 214.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Introducing mandatory VEGF testing for patients with acquired demyelinating neuropathy would lead to annual cost-savings of £107 398 for the National Health Service and could prevent misdiagnosis in 16 cases per annum.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Electrodiagnostic confirmation as a condition of reimbursement for efgartigimod in Canada
Approaches to treatment
Current treatment options and standard of care
Corticosteroids
Guideline recommendation for initial treatment
Certainty of randomized evidence for corticosteroids
“One non‐blinded RCT comparing prednisone with no treatment in 35 eligible participants did not measure the primary outcome for this systematic review.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neuropathy Impairment Scale scores after 12 weeks improved in 12 of 19 participants randomised to prednisone, compared with five of 16 participants randomised to no treatment (risk ratio (RR) for improvement 2.02 (95% confidence interval (CI) 0.90 to 4.52; very low‐quality evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was little or no difference in number of participants who achieved remission (RR 1.11; 95% CI 0.50 to 2.45 in favour of monthly dexamethasone; moderate‐quality evidence), or change in disability or impairment after one year (low‐quality evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, corticosteroids are commonly used in practice, supported by very low‐quality evidence from observational studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pulsed dexamethasone versus daily prednisolone: remission at 12 months
“The primary outcome measure was remission at 12 months, defined as improvement of at least three points on the Rivermead mobility index and improvement of at least one point on the inflammatory neuropathy cause and treatment disability scale.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between December, 2003, and December, 2008, 40 patients were treated: 24 received dexamethasone and 16 received prednisolone. At 12 months, 16 patients were in remission: ten in the dexamethasone group and six in the prednisolone group (odds ratio [OR] 1.2, 95% CI 0.3-4.4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most adverse events were minor and did not differ substantially between treatment groups; however, sleeplessness and Cushing's face occurred more often in the prednisolone group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term remission after corticosteroid courses
“Cure (>5 years off treatment) or remission according to the CDAS criteria after 1 or 2 courses of pulsed dexamethasone or daily prednisolone was achieved in 10 out of 39 patients (26%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Half of the patients who were in remission after initial treatment experienced a relapse (median treatment-free interval: 17.5 months for dexamethasone, 11 months for prednisolone).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intravenous methylprednisolone versus intravenous immunoglobulin over 6 months
“More patients stopped methylprednisolone (11 [52%] of 21) than IVIg (three [13%] of 24; relative risk 0·54, 95% CI 0·34-0·87; p=0·0085).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Reasons for discontinuation were lack of efficacy (eight in the methylprednisolone group vs three in the IVIg group), adverse events (one in the methylprednisolone group), or voluntary withdrawal (two in the methylprednisolone group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After therapy discontinuation, more patients on IVIg worsened and required further therapy (eight [38%] of 21) than did those on methylprednisolone (none of ten; p=0·0317).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral prednisolone versus intravenous immunoglobulin: randomized crossover trial
“This multicenter, randomized, double-blind, crossover trial compared a six week course of oral prednisolone tapering from 60 mg to 10 mg daily with intravenous immunoglobulin (IVIg) 2.0 g/kg given over one to two days for treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-four of the thirty-two randomized patients completed both treatment periods.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was slightly, but not significantly, more improvement after IVIg than with prednisolone, the mean difference between the groups in change in disability grade being 0.16 (95% CI = -0.35 to 0.66).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A serious adverse event (psychosis) attributable to treatment occurred in one patient while on prednisolone and in none with IVIg.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intravenous immunoglobulin
Guideline recommendation in motor CIDP
Immune globulin intravenous versus placebo: adjusted INCAT response through week 24
“117 patients with CIDP who met specific neurophysiological inflammatory neuropathy cause and treatment (INCAT) criteria participated in a randomised, double-blind, placebo-controlled, response-conditional crossover trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the first period, 32 of 59 (54%) patients treated with IGIV-C and 12 of 58 (21%) patients who received placebo had an improvement in adjusted INCAT disability score that was maintained through to week 24 (treatment difference 33.5%, 95% CI 15.4-51.7; p=0.0002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the extension phase, participants who continued to receive IGIV-C had a longer time to relapse than did patients treated with placebo (p=0.011).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of serious adverse events per infusion was 0.8% (9/1096) with IGIV-C versus 1.9% (11/575) with placebo. The most common adverse events with IGIV-C were headache, pyrexia, and hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled randomized evidence for intravenous immunoglobulin
“We included nine RCTs with 372 participants (235 male) from Europe, North America, South America, and Israel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IVIg compared with placebo increases the probability of significant improvement in disability within six weeks of the start of treatment (risk ratio (RR) 2.40, 95% confidence interval (CI) 1.72 to 3.36; number needed to treat for an additional beneficial outcome (NNTB) 4, 95% CI 3 to 5; 5 trials, 269 participants; high‐certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During this period, IVIg probably has similar efficacy to oral prednisolone and IVMP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further research is needed to assess the long‐term benefits and harms of IVIg relative to other treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single-arm induction and maintenance study: responder rate
“Patients received one induction dose of Privigen (2 g/kg body weight [bw]) and up to seven maintenance doses (1 g/kg bw) at 3-week intervals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall responder rate at completion was 60.7% (95% confidence interval [CI]: 42.41%–76.43%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two serious AEs of hemolysis were reported that resolved after discontinuation of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Maintenance dose-ranging study: response by dose
“Patients were randomized 1:2:1 to receive the standard intravenous immunoglobulin induction dose and then either 0.5, 1.0 or 2.0 g/kg maintenance doses every 3 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The response rate was 80% (55/69 patients) [95% confidence interval (CI): 69–88%] in the 1.0 g/kg group, 65% (22/34; CI: 48–79%) in the 0.5 g/kg group, and 92% (33/36; CI: 78–97%) in the 2.0 g/kg group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While the proportion of responders was higher with higher maintenance doses, logistic regression analysis showed that the effect on response rate was driven by a significant difference between the 0.5 and 2.0 g/kg groups, whereas the response rates in the 0.5 and 2.0 g/kg groups did not differ significantly from the 1.0 g/kg group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rescue treatment of relapse after subcutaneous immunoglobulin or placebo
“Overall, 20 patients received IVIG 10% ( n = 4 [fSCIG 10%‐relapse group]; n = 16 [placebo‐relapse group]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Responder rate (95% confidence interval) was 100.0% (80.6%–100.0%) in the placebo‐relapse group and 95.0% (76.4%–99.1%) in the overall‐relapse population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across all patients, median time to functional improvement was 25 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA-approved intravenous immunoglobulin products for CIDP: indications and dosing
Subcutaneous immunoglobulin
Guideline recommendation for maintenance treatment
Weekly subcutaneous immunoglobulin versus placebo: relapse or withdrawal over 24 weeks
“We randomly allocated participants to 0·2 g/kg or 0·4 g/kg of a 20% SCIg solution (IgPro20) weekly versus placebo (2% human albumin solution) for maintenance treatment for 24 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the intention-to-treat set, 36 (63% [95% CI 50-74]) patients on placebo, 22 (39% [27-52]) on low-dose SCIg, and 19 (33% [22-46]) on high-dose SCIg had a relapse or were withdrawn from the study for other reasons (p=0·0007).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Absolute risk reductions were 25% (95% CI 6-41) for low-dose versus placebo (p=0·007), 30% (12-46) for high-dose versus placebo (p=0·001), and 6% (-11 to 23) for high-dose versus low-dose (p=0·32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Causally related adverse events occurred in 47 (27%) patients (ten [18%] in the placebo group, 17 [30%] in the low-dose group, and 20 [34%] in the high-dose group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Facilitated subcutaneous immunoglobulin versus placebo: relapse over 6 months
“fSCIG 10% was administered at the same dose (or matching placebo volume) and interval as pre-randomization IVIG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CIDP relapse was reduced with fSCIG 10% versus placebo (n = 6 [9.7%; 95% confidence interval 4.5%, 19.6%] vs n = 22 [31.4%; 21.8%, 43.0%], respectively; absolute difference: -21.8% [-34.5%, -7.9%], p = .0045).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events (AEs) were more frequent with fSCIG 10% (79.0% of patients) than placebo (57.1%), but severe (1.6% vs 8.6%) and serious AEs (3.2% vs 7.1%) were less common.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term facilitated subcutaneous immunoglobulin extension: relapse and tolerability
“The study provided 220 patient‐years of follow‐up data from 85 patients. Median (range) exposure was 33 (0–77) months. Patients received fSCIG every 4 weeks (88.2%) or every 3 weeks (11.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relapse occurred in 10 of 77 patients (13.0%); annual relapse rate was 4.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“fSCIG‐related AEs ( n = 798) included infusion site reactions such as pain, redness, and pruritus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled randomized evidence for subcutaneous immunoglobulin
“Four RCTs with 360 randomised participants met our eligibility criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SCIg maintenance treatment probably reduces the risk of clinically significant deterioration in disability within 12 to 24 weeks compared to placebo (RR 0.40, 95% CI 0.28 to 0.56; 3 studies, 333 participants; moderate‐certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We could not evaluate the difference between SCIg and IVIg as induction treatment in terms of rate of improvement in disability, change in grip strength, or frequency of local or systemic adverse effects, as these data were not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA-approved subcutaneous immunoglobulin products for CIDP: indications and dosing
Plasma exchange
Guideline recommendation after failure of immunoglobulin and corticosteroids
Pooled randomized evidence for plasma exchange
“Primary outcome measure: one cross‐over trial including 18 participants showed after four weeks, 2 (95% confidence interval (CI) 0.9 to 3.1) points more improvement on an 11‐point disability scale with plasma exchange (10 exchanges over four weeks) than with sham exchange.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Non‐randomised evidence indicates that plasma exchange induces adverse events in 3% to 17% of procedures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events related to difficulty with venous access, use of citrate, and haemodynamic changes are not uncommon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma exchange versus sham exchange: parallel-group trial
“We performed a prospective double-blind trial in which patients with static or worsening disease were randomly assigned to plasma exchange (n = 15) or to sham exchange (n = 14) for three weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that for some patients with chronic inflammatory demyelinating polyradiculoneuropathy, plasma exchange has an ameliorating effect on neurologic dysfunction and nerve conduction, but in others no improvement is observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Plasma exchange versus sham exchange: double-blind crossover trial
“A primary 'intention to treat' analysis showed significant improvement with PE in all clinical outcome measures: NDS by 38 points, P < 0.001; CG by 1.6 points, P < 0.001; GS by +13 kg, P < 0.003” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that PE is a very effective adjuvant therapy for CIDP of both chronic progressive and relapsing course; concurrent immunosuppressive drug treatment is required.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Exchange treatments should be given two to three times per week until improvement is established; the treatment frequency should then be tapered over several months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Immunosuppressants and rituximab
Guideline recommendation when maintenance doses are high
Pooled randomized evidence for immunosuppressants and immunomodulators
“Four trials fulfilled the selection criteria: one of azathioprine (27 participants), two of IFN beta‐1a (77 participants in total) and one of methotrexate (60 participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the trials showed significant benefit in any of the outcomes selected by their authors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the trials was large enough to rule out small or moderate benefit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate versus placebo: corticosteroid or immunoglobulin dose reduction
“14 (52%) of 27 taking methotrexate and 14 (44%) of 32 taking placebo had a greater than 20% reduction in mean weekly dose of corticosteroids or intravenous immunoglobulin (adjusted odds ratio 1.21, 95% CI 0.40-3.70).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Oral methotrexate 15 mg weekly showed no significant benefit, but limitations in the trial design and the high rate of response in the placebo group meant that a treatment effect could not be excluded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rituximab versus placebo: worsening after immunoglobulin discontinuation
“In this randomized, double-blind, placebo-controlled study, conducted at seven Italian hospitals, CIDP patients under immunoglobulin therapy were assigned to receive either rituximab (1 g on Days 1, 15 and 180 ± 7) or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A similar proportion of patients in both the rituximab (12/19, 63.2%) and placebo (12/18, 66.6%) groups worsened at Month 12 [odds ratio (OR) 0.86; 95% confidence interval (CI) 0.22–3.32].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to worsening was 5 months for rituximab and 2 months for placebo (Log-rank P = 0.4372).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neonatal fc receptor blockers
FDA-approved neonatal Fc receptor blocker for CIDP: indication and dosing
Subcutaneous efgartigimod randomized withdrawal trial: response and relapse
“Participants with evidence of clinically meaningful deterioration entered an open-label phase of weekly 1000 mg subcutaneous efgartigimod PH20 for no longer than 12 weeks (stage A).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between April 15, 2020, and May 11, 2023, 629 participants were screened; 322 (114 female, 208 male) entered stage A, of whom 214 (66%, 95% CI 61·0-71·6) had confirmed ECI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subcutaneous efgartigimod PH20 significantly reduced the risk of relapse versus placebo (hazard ratio 0·39 [95% CI 0·25-0·61]; p<0·0001). 31 (27·9% [19·6-36·3]) participants given subcutaneous efgartigimod PH20 had a relapse versus 59 (53·6% [44·3-63·0]) given placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In stage B, TEAEs occurred in 71 (64%) participants on subcutaneous efgartigimod PH20 and 62 (56%) participants on placebo, and serious TEAEs in six (5%) on subcutaneous efgartigimod PH20 and six (5%) on placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension: long-term safety and function
“At interim data cut‐off (February 16, 2024), 228/229 eligible participants advanced to ADHERE+.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prolonged efgartigimod exposure did not increase the incidence ( n = 171/228 [75.0%]) or severity of TEAEs (grade ≥ 3 TEAEs, n = 41/228 [18.0%]); regardless of immunoglobulin G level, there was a low incidence of infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stage A responders reported long‐term clinically meaningful improvements in mean aINCAT (decreased by 1.2 points), I‐RODS centile metric (increase of 8.8 points), and GS scores (increase of 17.5 kPa) from run‐in baseline to ADHERE+ week 36, irrespective of stage B treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous efgartigimod randomized withdrawal trial: registry participant flow
Subcutaneous efgartigimod randomized withdrawal trial: registry results for stage B time-to-event and disability outcomes
| Stage B outcome | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Median time to first adjusted INCAT deterioration, days (95% CI) | “NA[1] (NA to NA)” | “140.0[2] (75.0 to NA)” |
| Median time to CIDP disease progression, days (95% CI) | “NA[1] (247.0 to NA)” | “85 (50.0 to 253.0)” |
| Mean (SD) change in adjusted INCAT score from stage B baseline | “0.1(1.08)” | “0.9(1.98)” |
Subcutaneous efgartigimod randomized withdrawal trial: registry definitions for stage B outcomes
Subcutaneous efgartigimod randomized withdrawal trial: registry all-cause mortality and serious adverse events
| Event | Stage A efgartigimod PH20 SC | Stage B efgartigimod PH20 SC | Stage B placebo PH20 SC |
|---|---|---|---|
| All-cause mortality, affected/at risk (%) | “2/322 (0.62%)” | “0/111 (0.00%)” | “1/110 (0.91%)” |
| Serious adverse events, affected/at risk (%) | “21/322 (6.52%)” | “6/111 (5.41%)” | “6/110 (5.45%)” |
Limitations of current therapies
Summary
Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment; Sanofi states that, in people with CIDP who respond, about 70% of the response is considered incomplete. Approximately two-thirds of patients need long-term intravenous immunoglobulin, and in a US claims analysis 62% of immunoglobulin users were chronic users during the first year after the index date. Biomarkers of disease activity are lacking: in a withdrawal trial, 41% of participants withdrawn from intravenous immunoglobulin remained stable for 24 weeks, compared with 58% who continued it, and the lack of biomarkers can lead to potential overtreatment. After plasma exchange, 8 of 12 responders relapsed within 7 to 14 days of stopping. About 30% of survey respondents receiving intravenous immunoglobulin missed school or work because of infusions, and subcutaneous immunoglobulin typically requires administration once or twice a week. The Gamunex-C prescribing information carries a boxed warning for thrombosis, renal dysfunction, and acute renal failure, and states that renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous products in predisposed patients; observational studies indicate that corticosteroids carry a long-term risk of serious side effects.
Non-response and incomplete response to available treatments
“Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment, highlighting the need for effective alternatives.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Some patients were dissatisfied by treatment outcomes (11.0%) and symptom control (12.2%). Overall, mean (SD) patient‐reported scores were 62.1 (20.4) for I‐RODS, 35.0 (11.1) for FACIT fatigue, and 0.662 (0.253) for EQ‐5D‐5L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term dependence on immunoglobulin
“Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of patients who used Ig, 62% ( n = 1,113) were chronic and 38% ( n = 690) were intermittent users during the 1-year post-index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A substantial proportion of Ig users were chronic users who also received other CIDP therapies, with steroids being most common. This suggests a potentially pronounced burden among patients treated with frequent Ig and steroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No biomarker of ongoing need for treatment, and overtreatment
“Biomarkers for disease activity are lacking, making the need for ongoing treatment difficult to assess, leading to potential overtreatment and high health-care costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the intravenous immunoglobulin withdrawal group, 41% remained stable for 24 weeks, compared to 58% in the intravenous immunoglobulin continuation group (−17%; 95% CI −39 to 8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the intravenous immunoglobulin withdrawal group, 28% remained stable at the end of the extension phase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“45/125 individuals met criteria for clinical stability, with median age 58 years, I‐RODS 37/48, MRC‐SS 69/70 and annual treatment costs £107 000/person.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“12 of 36 (33.3%) consented to cessation trial and eight of those (66.7%) remained stable off treatment for ≥ 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of infusions
“IVIg was associated with venous access issues and work/school absenteeism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“About 30% of respondents in each group that received IVIg missed school or work because of the infusions” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SCIG has fewer systemic adverse reactions than IVIG and can be administered at home by patients or caregivers, 8 but typically requires more frequent infusions, such as administration once or twice a week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (standard deviation) infusion duration was 135.5 (62.8) minutes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety limitations of immunoglobulin and corticosteroids
Place in treatment, anticipated use, and care setting
Summary
In a US claims analysis of 3,409 individuals with CIDP, 2,758 (81%) were treated during the first year, and steroids (73% of those treated) followed by immunoglobulin (65%) were the most commonly used treatments. Neurology specialists are the most frequent prescribers of immunoglobulin, which may be given in a hospital clinic, physician's office, infusion clinic, or at home; the Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) prefilled syringe may be administered subcutaneously by patients or caregivers after proper instruction, and the vial is to be administered by a healthcare professional only.
The company positions claseprubart as a potential first-line biologic given as a subcutaneous, infrequently dosed, self-administered injection, and CAPTIVATE enrolls standard-of-care-refractory, standard-of-care-treated, and standard-of-care-naive patients without requiring immunoglobulin withdrawal. Other complement inhibitors are in development: Sanofi announced that the phase 3 MOBILIZE trial of riliprubart, an antibody that selectively inhibits activated C1s, in CIDP refractory to standard-of-care treatment will be stopped after an independent data monitoring committee determined at an interim analysis that it is unlikely to provide sufficient efficacy, and that continuation of VITALIZE will be evaluated accordingly; argenx is advancing two phase 3 trials of empasiprubart, an antibody targeting C2, one of them a head-to-head comparison with intravenous immunoglobulin.
Current US treatment patterns
“Among patients who received treatment in 2023, a majority in both cohorts received steroids, followed by immunoglobulin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients in both cohorts were most frequently seen by neurology specialists, and these specialists were the most frequent prescribers of immunoglobulin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 3,409 patients with CIDP identified, the majority (81% [ n = 2,758]) were treated for CIDP while 19% ( n = 651) were untreated for CIDP during 1-year post-index. Steroids (73% [ n = 2017]) followed by Ig (65% [ n = 1,803]) were most commonly utilized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting for current infused and injected therapies
“Immunoglobulin may be administered at a hospital clinic, physician’s office, free-standing infusion clinic, or at home with proper monitoring” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When the costs were evaluated by site of care, home infusion visits were a primary site of care in CIDP-specific costs for the patients receiving IVIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company positioning of claseprubart in CIDP
Company-sponsored survey of US neurologists on unmet need
Investigational complement inhibitors in CIDP
Riliprubart phase 3 trials: refractory and immunoglobulin-treated populations
Riliprubart MOBILIZE trial stopped for insufficient efficacy
Empasiprubart phase 3 trials
Riliprubart MOBILIZE: refractory population, enrollment, and status in the registry record
Riliprubart VITALIZE: population maintained on intravenous immunoglobulin in the registry record
Empasiprubart EMNERGIZE: untreated and treated participants switching to study drug in the registry record
Empasiprubart EMVIGORATE: population treated with intravenous immunoglobulin in the registry record
Heterogeneity of treatment effect
Typical CIDP and CIDP variants
“Patients were diagnosed with typical CIDP (69.2%) and variant CIDP (30.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A diverse and complex interplay of different immunopathological mechanisms, involving cellular, humoral and complement pathways, culminates in a highly variable pattern of peripheral nerve damage in different clinical variants of CIDP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody-mediated nodopathies: response to standard therapy
“A breakthrough in CIDP antibody autoimmunity has been the remarkable observation that a subset of patients who do not respond to IVIg or plasmapheresis have IgG4 antibodies to nodal/paranodal antigens directed against neurofascin-155 (Nfasc155), neurofascin-140/186 (Nfasc140/186), contactin-1 (CNTN1), and contactin-associated protein 1 (Caspr1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because the IgG4 antibodies do not trigger inflammatory processes or complement-mediated immune responses, the conventional anti-inflammatory therapies, especially with IVIg, immunosuppressants, and plasmapheresis, are ineffective or not sufficiently effective in inducing long-term remissions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Indeed, data from large series of patients with MuSK myasthenia, CIDP with nodal/paranodal antibodies, and anti-LGI1 and CASPR2-associated syndromes indicate that B cell depletion therapy with rituximab exerts long-lasting clinical remissions by targeting memory B cells and IgG4-producing CD20-positive short-lived plasma cells.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody subclass and expected relevance of complement inhibition
“It is noteworthy that almost all the antibodies to these paranodal antigens were IgG4, an IgG subclass that is non-complement fixing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonetheless, some variants of these neuropathies harbor IgG1-3 subclass of antibodies with ability to fix complement and could potentially be candidates to complement inhibition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, complement involvement in certain subgroups of CIDP patients, including those with non-complement fixing antibodies, is not yet certain” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Response by disease course to plasma exchange
“Fifteen patients completed the trial and of those, 12 patients (80%) improved substantially with PE; i.e. five out of seven patients with chronic progressive course and seven out of eight patients with relapsing CIDP improved.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The PE non-responders improved with prednisone.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Non-response and alternative diagnoses
“Alternative diagnosis was made in 7 out of 12 (58%) who did not respond to any therapy and in none of the treatment-responsive patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In treatment-nonresponsive patients, the diagnosis CIDP should be reconsidered.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Activated C1s inhibition by standard-of-care group: riliprubart phase 2
Neonatal Fc receptor blockade by prior treatment status
Care management intervention strategies
Immunoglobulin dose optimization and cessation trials
“Periodic IVIG optimization trials using objective outcomes are encouraged in all CIDP patients receiving chronic IVIG treatment as a means to identify the lowest effective IVIG dose and frequency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both groups, drug‐free remission was achieved in about one‐third of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The successful cessation trials resulted in a cost saving of £855 000/year, with a potential further saving of £1.7 million/year if all the eligible individuals had consented.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients who deteriorated were rescued to previous baseline on retreatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with CIDP should be counselled about the natural history of the disease and future scheduled, targeted cessation trials. A dedicated clinical infrastructure is vital to safely perform cessation trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous immunoglobulin dose reduction
“After dose reduction from 0.4 to 0.2 g/kg, 51% (27/53) of patients relapsed, of whom 92% (24 of 26) improved after reinitiation of the 0.4 g/kg dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two-thirds of patients (19/28) who completed the PATH study without relapse remained relapse-free on the 0.2 g/kg dose after dose reduction in the extension study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term dosing should be individualized to find the most appropriate dose in a given patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Home and subcutaneous administration
“Eight consecutive patients, four with MMN and four with CIDP, already on long-term, hospital-based IVIG were switched to home-based SCIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In seven of the eight patients, SCIG gave improved tolerability and patient satisfaction with similar efficacy compared with IVIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most important factors in treatment decision-making were a lower chance of CIDP symptom worsening in 6 months, less frequent treatment administration, and home infusion (all p < 0.001 vs reference categories).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, like conventional SCIG, fSCIG 10% offers the potential convenience of home administration, 13 leading to possible cost savings and eliminating burden of travel to an infusion center or other facility over multiple days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Home infusions are generally safe, effective, convenient, and less costly than infusions in other sites of care (eg, physician office, outpatient hospital), making this a frequently used site of care for infusions, either by choice or through health plan benefit design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcome monitoring with disability, strength, and patient-reported scales
“Assessing strength impairment, disability, and quality of life is ideally suited for everyday practice when caring for patients with CIDP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Such data are critically important when justifying the need for ongoing or periodic immunotherapy, documenting relapse or deterioration, or providing reassurance of disease improvement, stability, or remission.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Frequent assessment of grip strength can be a useful tool to identify intravenous immunoglobulin (IVIG) treatment‐related fluctuations (TRFs) and optimize IVIG treatment in real‐time, but the long‐term implications of TRFs are unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint in stage A, evaluated in the stage A safety population, was confirmed ECI (≥1 points aINCAT decrease, ≥4 points [centile metric] Inflammatory Rasch-built Overall Disability Scale increase, or ≥8 kPa grip strength increase after four injections and two consecutive visits).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Remote monitoring of grip strength and patient-reported outcomes
“Patients were monitored weekly or monthly, based on stability and patient preference, using grip strength, modified timed‐up‐and go (mTUG), and patient‐reported outcome measures (PROMs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adherence was 93% (95% CI: 91.9%–94.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grip strength and mTUG ICCs were both 0.96 (95% CI: 0.93–0.98 and 0.92–0.99, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.